A recent review encompassing safety data from the GH registries of various pharmaceutical companies between 1988 and 2016 showed no evidence of an increased risk of new malignancy, leukemia, brain tumor, or recurrence of malignant brain tumor in children treated with GH without any other risk factors [11]. The gene discussed is GH1; the disease is brain cancer.